S.MAMEDE DO CORONADO, Portugal and LONDON, April 28 /PRNewswire/ --
- New Option for Treatment of Epilepsy Patients With Partial Onset Seizures
Bial-Portela CA, S.A., (S. Mamede do Coronado, Portugal, President CEO Dr Luis Portela), and Eisai Europe Limited (London; Chairman CEO Yutaka Tsuchiya), the European subsidiary of Eisai Co., Ltd. (Tokyo, President CEO: Haruo Naito), today announced that the novel once daily anti-epileptic Zebinix(R)* (eslicarbazepine acetate) received marketing authorisation from the European Commission as adjunctive therapy in adults with partial-onset seizures, with or without secondary generalisation.